{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~4 mi. (Torquay, United Kingdom, +226 more cities)
facility
Torbay Hospital ( Site 0532)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~4 mi. (Torquay, United Kingdom, +159 more cities)
facility
Torbay Hospital ( Site 0704)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~4 mi. (Torquay, United Kingdom, +92 more cities)
facility
South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 0444)
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~25 mi. (Exeter, United Kingdom, +147 more cities)
facility
Royal Devon and Exeter Foundation Trust Hospital ( Site 0699)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
city
~25 mi. (Exeter, United Kingdom, +160 more cities)
facility
Royal Devon and Exeter Hospital (Wonford)
condition
Fallopian Tube Carcinoma, +2 more conditions
drug type
chemotherapy, +1 more type
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~59 mi. (Taunton, United Kingdom, +127 more cities)
facility
Taunton and Somerset Hospital ( Site 2900)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type